FINO
FINAL DECISION TRANSACTION PROCESSED BY IB
04/04/2025
Back to search
Official data from USPTO
TAZOVID
Did you know this trademark is already registered in United States?
Before investing in name, identity, and promotion, validate collision risk and registration strategy to avoid wasting time and budget.
Active USPTO registrationType: WordOffice: US
Risk and opportunity diagnosis
Executive reading for naming, filing, and monitoring decisions.
USPTO status
Active USPTO registration
Case type
Application and registration
Recorded events
26
Latest update
04/03/2026
Classification
Registered
Trademark type
Word
Nice classes
5
Filing date
04/13/2023
Registration date
10/08/2024
Expiration date
-
Recommended action
Perform a full collision analysis and validate classes before any filing or trademark investment.
Next step
These are the details of the registration process. Even so, constant monitoring is what ensures peace of mind that your main asset remains protected.
Complete case details
Structured fields from the responsible authority and the official record.
Status date
10/08/2024
Last transaction
04/03/2026
Responsible office
United States Patent and Trademark Office
Status code
700
Official register
Principal Register
Drawing code
4
Owner type
99
Owner location
CN
Examiner
EISNACH, MICHAEL PATRICK
Law office
L40
Current location
FILE REPOSITORY (FRANCONIA)
Holders and representatives
Holders
FUJIAN COSUNTER PHARMACEUTICAL CO., LTD.
Representatives
Michelle P. Ciotola Cantor Colburn LLP
Technical classification
Nice Classes
Class 5
Vienna Codes
No Vienna codes available.
Goods and services
Class 5
Medicines for human purposes for the treatment of insomnia, amnesia, asthenia, neurasthenia, chronic chest diseases, chronic tracheitis and bronchitis, coronary thrombosis, fever, influenza, vertigo, hyperlipidemia, adiposity, obesity and COVID-19; Pharmaceutical preparations for the treatment of insomnia, amnesia, asthenia, neurasthenia, chronic chest diseases, chronic tracheitis and bronchitis, coronary thrombosis, fever, influenza, vertigo, hyperlipidemia, adiposity, obesity and COVID-19; Capsules being medicines for the treatment of insomnia, amnesia, asthenia, neurasthenia, chronic chest diseases, chronic tracheitis and bronchitis, coronary thrombosis, fever, influenza, vertigo, hyperlipidemia, adiposity, obesity and COVID-19; Drugs for medical purposes for the treatment of insomnia, amnesia, asthenia, neurasthenia, chronic chest diseases, chronic tracheitis and bronchitis, coronary thrombosis, fever, influenza, vertigo, hyperlipidemia, adiposity, obesity and COVID-19; vaccines; Ointments for pharmaceutical purposes for the treatment of skin conditions; Medicines in the form of tablets for the treatment of insomnia, amnesia, asthenia, neurasthenia, chronic chest diseases, chronic tracheitis and bronchitis, coronary thrombosis, fever, influenza, vertigo, hyperlipidemia, adiposity, obesity and COVID-19; biocides; Dietetic preparations adapted for medical purposes; Depuratives for the body; Medicines for veterinary purposes for the treatment of COVID-19; dental lacquer
Publications
History of USPTO decisions and trademark events.
26 publications found
FICS
FINAL DISPOSITION NOTICE SENT TO IB
03/18/2025
FIMP
FINAL DISPOSITION PROCESSED
03/18/2025
FICR
FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB
01/08/2025
NRCC
NOTICE OF REGISTRATION CONFIRMATION EMAILED
10/08/2024
R.PR
REGISTERED-PRINCIPAL REGISTER
10/08/2024
NPUB
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
07/23/2024
PUBO
PUBLISHED FOR OPPOSITION
07/23/2024
NONP
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
07/03/2024
CNSA
APPROVED FOR PUB - PRINCIPAL REGISTER
06/14/2024
XAEC
EXAMINER'S AMENDMENT ENTERED
06/14/2024
GNEN
NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED
06/14/2024
GNEA
EXAMINERS AMENDMENT E-MAILED
06/14/2024
CNEA
EXAMINERS AMENDMENT -WRITTEN
06/14/2024
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
06/13/2024
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
06/13/2024
TROA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
06/13/2024
RFNT
REFUSAL PROCESSED BY IB
02/19/2024
RFCS
NON-FINAL ACTION MAILED - REFUSAL SENT TO IB
02/01/2024
RFRR
REFUSAL PROCESSED BY MPU
02/01/2024
RFCR
NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW
01/18/2024
CNRT
NON-FINAL ACTION WRITTEN
01/17/2024
DOCK
ASSIGNED TO EXAMINER
01/10/2024
MAFR
APPLICATION FILING RECEIPT MAILED
06/27/2023
NWOS
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
06/23/2023
REPR
SN ASSIGNED FOR SECT 66A APPL FROM IB
06/22/2023
Continuous trademark protection
Get notified about every new filing that threatens TAZOVID or your mark.
Professional 24-month watch service: we monitor USPTO for you and alert you in time to oppose — before conflicts become losses.